Cipla Ltd.
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 1935-01-01
- Employees
- 40.9K
- Market Cap
- -
- Website
- http://www.cipla.com
Clinical Trials
184
Active:11
Completed:129
Trial Phases
5 Phases
Phase 1:2
Phase 2:2
Phase 3:30
+2 more phases
Drug Approvals
22
NMPA:10
PHILIPPINES:5
FDA:4
+2 more agencies
Drug Approvals
Levothyroxine Sodium Tablets
- Product Name
- 左甲状腺素钠片
- Approval Number
- 国药准字HJ20240128
- Approval Date
- Nov 5, 2024
NMPA
Levothyroxine Sodium Tablets
- Product Name
- 左甲状腺素钠片
- Approval Number
- 国药准字HJ20240127
- Approval Date
- Nov 5, 2024
NMPA
Esomeprazole Magnesium for Delayed-Release Oral Suspension
- Product Name
- 艾司奥美拉唑镁肠溶干混悬剂
- Approval Number
- 国药准字HJ20233132
- Approval Date
- Feb 28, 2023
NMPA
Esomeprazole Magnesium for Delayed-Release Oral Suspension
- Product Name
- 艾司奥美拉唑镁肠溶干混悬剂
- Approval Number
- 国药准字HJ20233133
- Approval Date
- Feb 28, 2023
NMPA
Esomeprazole Magnesium for Delayed-Release Oral Suspension
- Product Name
- 艾司奥美拉唑镁肠溶干混悬剂
- Approval Number
- 国药准字HJ20233134
- Approval Date
- Feb 28, 2023
NMPA
Clinical Trials
Distribution across different clinical trial phases (156 trials with phase data)• Click on a phase to view related trials
Phase 4
81 (51.9%)Not Applicable
41 (26.3%)Phase 3
30 (19.2%)Phase 1
2 (1.3%)Phase 2
2 (1.3%)BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma
Phase 3
Completed
- Conditions
- Bronchial Asthma
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Cipla Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06154304
- Locations
- 🇺🇸
Velocity CLinical Research, Medford, Oregon, United States
BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation AerosolDrug: Placebo
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Cipla Ltd.
- Target Recruit Count
- 1485
- Registration Number
- NCT05322707
- Locations
- 🇺🇸
Velocity Clinical Research, Medford, Oregon, United States
BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients
Phase 3
Completed
- Conditions
- Bronchial Asthma
- Interventions
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Cipla Ltd.
- Target Recruit Count
- 1366
- Registration Number
- NCT03394989
- Locations
- 🇺🇸
Combined Research Orlando, Orlando, Florida, United States
Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma
Phase 3
Completed
- Conditions
- Bronchial Asthma
- Interventions
- Drug: PlaceboDrug: 180 mcg Reference ProductDrug: 90 mcg Reference ProductDrug: 90 mcg Test Product
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- Cipla Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT02624505
- Locations
- 🇺🇸
Colorado Allergy and Asthma Centers, Denver, Colorado, United States
News
Indian Pharma Companies Win Major Generic Drug Supply Contracts in China's Healthcare Market
Indian pharmaceutical companies including Hetero Labs, Cipla, Annora Pharma, and Natco Pharma have successfully won bids to supply generic drugs to Chinese hospitals through the country's volume-based procurement process.